Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Increases Public Offering to Up to $15.6M

NEW YORK (GenomeWeb) – OpGen today raised the amount it plans to publicly offer in stocks and warrants to up to $15.6 million,

The firm previously said it planned to offer up to $10 million in stocks and warrants.

OpGen said in an amended prospectus filed with the US Securities and Exchange Commission that it has not priced the offering but said that it will offer 13.7 million shares of its common stock and warrants to purchase an aggregate of more than 6.8 million shares of its common stock. Net proceeds from the offering are estimated at $8.5 million, based on an assumed offering price of $.73 per share of common stock. If the warrants are exercised in full at an exercise price of $.73 per share, net proceeds will increase by $5 million, the firm said.

Last week, OpGen said that it was warned by Nasdaq that it faced possible delisting action because its shares fell below a minimum bid price of $1 per share.The company was also warned in May that it is non-compliant with a listing requirement calling for a minimum of $2.5 million in stockholders' equity.

In afternoon trading on Thursday, shares of OpGen on the Nasdaq were down 3 percent to $.72 per share.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.